ob777

ob777 Samagi Jana Balawegaya (SJB) Galle district MP Gayantha Karunathilaka has been named the Chief Opposition Whip, following a meeting of the SJB Parliamentary group held yesterday evening. Karunathilaka, a veteran Parliamentarian has previously served as Chief Opposition Whip in January 2020 as well while representing the United National Party (UNP). From 2015 to 2019, he held the position of Chief Government Whip in the UNP-led Good Governance administration. During the same period, Karunathilaka served as Mass Media Minister and acted as the Cabinet Media Spokesperson. During his political career lasting 24 years he has also held other notable roles, including Lands and Parliamentary Affairs Cabinet Minister.

AP News Summary at 6:21 p.m. ESTAcquitted accused’s counsel sends notice to Rahul, seeks ₹50 lakh compensation

None

New Delhi [India], December 28 (ANI): The Supreme Court on Saturday raised serious concern on some farmer leaders not allowing Jagjit Singh Dallewal, who is on a fast-unto-death since November 26, to be shifted to hospital due to his deteriorating health condition. "Please communicate to them that those who are resisting Dallewal's hospitalisation are not his well wishers," a bench of Justices Surya Kant and Sudhanshu Dhulia told Punjab Chief Secretary who was appearing before the bench through video conferencing. Also Read | Tom Cruise's Upcoming Film With Alejandro Gonzalez Inarritu to Hit Theaters on October 2, 2026. It also expressed dissatisfaction on the Punjab government's argument that the state was "helpless and saddled" as other protesting farmers were obstructing its attempts to secure medical aid to Dallewal. "If state machinery says you are helpless, then do you know what is the repercussion. You are a constitutionally elected government... Court is not saying use unwanted force," said Justice Kant. Also Read | ISRO's SpaDeX Mission Set for December 30 Launch To Achieve Historic Space Docking Feat: Minister of Science and Technology Dr Jitendra Singh. Punjab Advocate General Gurminder Singh told the apex court that "Farmers are keeping close vigil around the protest site. If a move is made to take him somewhere, then..." Reacting to it, Justice Kant said, "So long as the gathering is there for the purpose of the demands raised by farmers, it is understandable. That is peaceful agitation for the purpose of raising their demands, and voice in a democratic manner... But gathering of farmers to prevent a person from shifting to the hospital, who requires immediate medical aid, is something which is completely unheard of." Justice Dhulia added, "This is actually abetment to suicide... You first create a problem and then take a plea, now that there is a problem we cannot do anything." It said that government has to comply with the December 20 order of the top court to provide medical aid to Dallewal and to convince him to go to a hospital if necessary. During the hearing, Chief Secretary and Director General of Police (DGP) of Punjab government told the bench that if the evacuation of Dallewal is not peaceful considering that the farmers are resisting his shifting, there would be "collateral damage". "If there is resistance to a lawful action, you will have to face it and meet it with whatever the law enforcement agencies do it normally... What appears to be the scenario is that Dallewal is refusing despite the fact that his health is not supporting him... He appears to be under the peer pressure," Justice Kant said. "There are some farmers leaders, we don't want to comment on their conduct. What kind of leaders are they if they are allowing him to die there? Please try to read in between the lines. Who are these people? Are they interested in Dallewal's life or do they want him to die there at spot? Their intention is questionable. We don't want to comment on what kind of conduct they are exhibiting... Even if you shift him to the hospital, you can assure Dallewal that you will not allow him to break his fast. A person with medical aid can also continue that," said the bench. The bench also questioned Central government asking what is it doing to diffuse the situation. Even a word from Union can help diffuse the situation, said Justice Dhulia. Passing the order, the apex court said it is not satisfied with the efforts of the State of Punjab regarding compliance of its orders dated December 20 and on assurance by Advocate General of Punjab, Chief Secretary and DGP it granted more time to take appropriate steps to comply with its directions. The bench said if the state of Punjab requires any assistance, Central government to give all requisite support to ensure compliance with court's directions. The top court said it will hear the case next on December 31. The apex court was hearing a contempt petition against its Chief Secretary and DGP of Punjab for non-compliance with December 20 top court order regarding medical aid to Dallewal and to convince him to go to hospital. It had on Friday issued notice to the Chief Secretary and DGP to file a compliance report by Saturday. Dallewal, the convener of the Samyukta Kisan Morcha (Non-Political) has been on a fast-unto-death at the Khanouri border to press the Centre to accept the farmers' demands, including a legal guarantee of minimum support price (MSP) for crops. The top court has been asking Punjab government to ensure Dallewal gets proper medical aid during fast-unto-death. (ANI) (This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)

Mutual of America Capital Management LLC cut its stake in Ryder System, Inc. ( NYSE:R – Free Report ) by 6.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,394 shares of the transportation company’s stock after selling 1,701 shares during the period. Mutual of America Capital Management LLC’s holdings in Ryder System were worth $3,411,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors have also recently modified their holdings of R. Natixis Advisors LLC grew its stake in shares of Ryder System by 15.2% in the 3rd quarter. Natixis Advisors LLC now owns 102,756 shares of the transportation company’s stock worth $14,982,000 after buying an additional 13,586 shares during the last quarter. KBC Group NV boosted its stake in Ryder System by 21.9% in the 3rd quarter. KBC Group NV now owns 1,232 shares of the transportation company’s stock worth $180,000 after purchasing an additional 221 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Ryder System during the 3rd quarter valued at about $396,000. Sigma Planning Corp bought a new stake in Ryder System during the 3rd quarter valued at about $208,000. Finally, Atria Investments Inc raised its holdings in Ryder System by 3.5% in the third quarter. Atria Investments Inc now owns 3,759 shares of the transportation company’s stock worth $548,000 after buying an additional 126 shares during the last quarter. 87.47% of the stock is currently owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth R has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. cut their price target on shares of Ryder System from $148.00 to $144.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Robert W. Baird boosted their price target on Ryder System from $140.00 to $155.00 and gave the stock an “outperform” rating in a research note on Friday, July 26th. Finally, StockNews.com cut Ryder System from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $140.57. Ryder System Price Performance NYSE R opened at $165.72 on Friday. The stock has a market capitalization of $7.01 billion, a price-to-earnings ratio of 15.50 and a beta of 1.28. Ryder System, Inc. has a 1-year low of $105.09 and a 1-year high of $170.20. The company has a debt-to-equity ratio of 2.17, a current ratio of 0.74 and a quick ratio of 0.74. The business’s fifty day moving average price is $150.57 and its 200-day moving average price is $136.42. Ryder System ( NYSE:R – Get Free Report ) last posted its earnings results on Thursday, October 24th. The transportation company reported $3.44 earnings per share for the quarter, beating analysts’ consensus estimates of $3.39 by $0.05. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.29 billion. Ryder System had a return on equity of 16.78% and a net margin of 3.83%. Ryder System’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.58 earnings per share. On average, equities analysts predict that Ryder System, Inc. will post 12.01 earnings per share for the current year. Ryder System Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, December 20th. Investors of record on Monday, November 18th will be given a dividend of $0.81 per share. The ex-dividend date is Monday, November 18th. This represents a $3.24 annualized dividend and a yield of 1.96%. Ryder System’s dividend payout ratio (DPR) is 30.31%. Insider Buying and Selling at Ryder System In other news, insider Thomas M. Havens sold 4,000 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $157.44, for a total transaction of $629,760.00. Following the completion of the sale, the insider now owns 20,504 shares of the company’s stock, valued at $3,228,149.76. The trade was a 16.32 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link . 5.10% of the stock is owned by corporate insiders. Ryder System Profile ( Free Report ) Ryder System, Inc operates as a logistics and transportation company worldwide. It operates through three segments: Fleet Management Solutions (FMS), Supply Chain Solutions (SCS), and Dedicated Transportation Solutions (DTS). The FMS segment offers full-service leasing and leasing with flexible maintenance options; commercial vehicle rental services; and contract or transactional maintenance services of trucks, tractors, and trailers; access to diesel fuel; and fuel planning and tax reporting, cards, and monitoring services, and centralized billing, as well as sells used vehicles through its retail sales centers and www.ryder.com/used-trucks website, as well as digital and technology support services. Featured Articles Want to see what other hedge funds are holding R? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ryder System, Inc. ( NYSE:R – Free Report ). Receive News & Ratings for Ryder System Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ryder System and related companies with MarketBeat.com's FREE daily email newsletter .

Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It's a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person's response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn't happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It's not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn't respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I'm hoping it's slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content. Jonel Aleccia, The Associated Press

Technology donations to create social good. (PRNewsfoto/Human-I-T) Holiday Mix & Match Deal puts tech and accessories under your tree for $200 or less!

Does Mukesh Ambani's wife, Nita Ambani, owns Falcon Supernova iPhone 6 Pink, which is world's most expensive phone?